A powerful cholesterol-lowering drug may be changing the rules of heart disease prevention. Researchers found that evolocumab, typically used for people who already have cardiovascular disease, can ...

Steven E. Nissen, M.D., of the Cleveland Clinic, and colleagues identified patients with muscle-related adverse effects from statins and compared lipid-lowering efficacy for two nonstatin therapies, ...

PARIS — Adding the PCSK9 inhibitor evolocumab (Repatha, Amgen) to high-intensity statin therapy in the very high-risk setting of acute coronary syndrome (ACS) safely lowers low-density lipoprotein ...

Mass General Brigham researchers found that the intensive cholesterol‑lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high‑risk patients who did not have known ...

Having high cholesterol in the blood can lead to a buildup called “plaque” on the walls of the arteries, raising the risk of cardiovascular disease. - Mohammed Haneefa Nizamudeen/iStockphoto/Getty ...

Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny—and what nuances do you need to know? Let’s dig in.

Mass General Brigham researchers found that the intensive cholesterol‑lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high‑risk patients who did not have known ...

Amgen (NASDAQ: AMGN) today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 – Sept. 2 in London. Data ...

CHICAGO, IL (updated) — Six-month treatment with the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab (Repatha, Amgen) can dramatically reduce LDL-cholesterol levels in ...

(CNN) — For some people with high cholesterol, making lifestyle changes and taking routine statin medications may not be sufficient to help them reach their target cholesterol levels. For these ...